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A B S T R A C T
The aim of the present study was to investigate virtual population pharmacokinetic using
physiologically based pharmacokinetic (PBPK) model for evaluating bioequivalence of oral
lacidipine formulations in dogs. The dissolution behaviors of three lacidipine formulations
including one commercial product and two self-made amorphous solid dispersions (ASDs)
capsules were determined in 0.07%Tween 80 media. A randomized 3-period crossover design
in 6 healthy beagle dogs after oral administration of the three formulations at a single dose
of 4 mg was conducted.The PBPK modeling was utilized for the virtual bioequivalence study.
In vitro dissolution experiment showed that the dissolution behaviors of lacidipine amor-
phous solid dispersions (ASDs) capsules, which was respectively prepared by HPMC-E5 or
Soluplus, as polymer displayed similar curves compared with the reference formulation in
0.07% Tween 80 media. In vivo pharmacokinetics experiments showed that three formula-
tions had comparable maximum plasma drug concentration (Cmax), and the time (Tmax) to
reach Cmax of lacidipine tablet, which was prepared by Soluplus, as polymer was slower than
other two formulations in consistency with the in vitro dissolution rate. The 90% confi-
dence interval (CI) for the Cmax, AUC0–24 h and AUC0–∞ of the ratio of the test drug to the reference
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drug exceeded the acceptable bioequivalence (BE) limits (0.80–1.25). However, the 90% CI of
the AUC0–24 h, AUC0–∞ and Cmax of the ratio of test to reference drug were within the BE limit,
calculated using PBPK modeling when the virtual subjects reached 24 dogs. The results all
demonstrated that virtual bioequivalence study can overcome the inequivalence caused
by inter-subject variability of the 6 beagle dogs involved in in vivo experiments.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
During the generic drug approval process, the approvement for
marketing requires that the generic drug demonstrate both
pharmaceutical equivalence and BE between the generic
product and its corresponding reference formulation (R) [1]. BE
studies are an integral component of the new drug develop-
ment process and played an important role in the approval and
marketing of generic drug products [2]. Generally, in vivo
bioequivalence studies are conducted using a single-dose, ran-
domized, two-period crossover design [3]. The plasma
concentration profile of the generic drug product is com-
pared to that of reference, and two products are considered
to be bioequivalent if they show the same rate and extent of
absorption [2]. According to the criteria developed by the U.S.
Food and Drug Administration and generally applied by other
regulatory agencies, the test and reference formulations were
considered to be bioequivalent when the 90% confidence in-
terval of the geometric mean ratios of Cmax, AUC0–t and AUC0–∞
between the reference and the test formulations was within
the range of 80.00%–125.00% [2].
However, the results of a BE study can be impacted by factors
including sample size and variability other than true differ-
ences in Cmax and/or AUC between the test formulations and
the reference formulation [4]. Enhancing the experimental
subject size or utility accurate simulation model will be de-
sirable. Usually, the researchers conducted the BE study with
a large number of subject, which would result in great cost and
high labor. Physiologically based pharmacokinetic (PBPK) model
is such a feasible mechanistic tool to predict the PK of drug
products for virtual bioequivalent study.
PBPK model is a mathematical model that integrates physi-
cochemical properties of drug substances, formulation
properties of drug products and physiological parameters of
animals to predict absorption, distribution,metabolism and ex-
cretion of compounds in vivo [5–7]. A large number of
methodologies including allometric scaling [8–11] and physi-
ologically based pharmacokinetic (PBPK)model [12,13] have been
established for PK prediction. PBPK model is a more compre-
hensive mechanistic tool to predict the optimized PK
parameters, and predict plasma and tissue concentration–
time profiles of drug products than conventional model [14,15].
Additionally, use of PBPK models enables the prediction of
human plasma concentration time profiles with minimal (and
in some cases no) animal data [5]. Currently, population phar-
macokinetics simulation by using the PBPK model to obtain
the PK of drug products from large subjects has not been dis-
cussed and explored extensively.
In this work, the aim of the present study was to investi-
gate virtual population pharmacokinetic using PBPK model for
evaluating bioequivalence of oral lacidipine formulations in
dogs. The dissolution behaviors of three lacidipine formula-
tions were determined in 0.07%Tween 80 media. A randomized
3-period crossover design in 6 healthy beagle dogs after oral
administration of three formulations at a single dose of 4 mg
was conducted. The physiologically based pharmacokinetic
(PBPK) model was utilized for virtual BE studies. In summary,
the virtual BE studies will enhance the accuracy of the experi-
ment of bioequivalence with minimal animal data and reduce
repeated in vivo experiment.
2. Materials and methods
2.1. Materials
Lacidipine was purchased from Kangya of NingXia Pharma-
ceuticals Co. Ltd. (Ningxia, China). Soluplus and HPMC-E5 were
gifts from BASF Co., Ltd. (Shanghai, China). Capsule shell was
purchased from Suzhou Capsule Co. Ltd. (Suzhou, China).
Sodium hydroxide pellets, sodium chloride, sodium dihydrogen
phosphate monohydrate, ethanol, dichloromethane andTween
80 were analytical grade and purchased from Tianjin Bodi
Chemical Holding Co. Ltd. (Tianjin, China). Formic acid was pur-
chased from Dikma Scientific Inc. (Beijing, China). Methanol,
acetonitrile and tert-butyl methyl ether were of chromato-
graphic grade and purchased fromThermo Fisher Scientific Inc.
(USA). Heparin sodium was purchased fromTianjin Biochem-
istry Pharmaceuticals Co. Ltd. (Tianjin, China). Nimodipine
reference substance was purchased from the National Insti-
tutes for Food and Drug Control (Beijing, China). Deionized-
distilled water was used throughout the study.
2.2. Formulations
Three formulations of lacidipine were determined in this study.
The reference formulation of lacidipine (R) was LACIPIL® 4 mg
tablet (GlaxoSmithKline, England). Two test formulations of
lacidipine were capsules that respectively contain two kinds
of lacidipine amorphous solid dispersion.The amorphous solid
dispersions (ASDs) were prepared via solvent evaporation tech-
nique. Two ASDs were prepared by the following step: Drug/
polymer weight ratios of lacidipine and polymers were 1:12.5.
One polymer was HPMCE5 (T1), while another was Soluplus (T2).
Then lacidipine and polymers were dissolved in a 1:1 v/v
mixture of dichloromethane and ethanol, and organic
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solvents were removed by rotary evaporation.The samples were
dried under vacuum for about 12 h at room temperature. The
dried samples formed a uniform and free flowing powder by
passing through the 80 mesh sieve.
2.3. Media preparation
The compositions of the blank fasted state intestinal fluid (Blank
FaSSIF) [16] were summarized in Table 1. The 0.07% Tween 80
media was prepared by adding 0.7 gTween 80 to 1 l blank FaSSIF.
2.4. Dissolution tests
Dissolution experiments were conducted according to the USP
Apparatus 2 (Paddle) setup (ZRS-8G; Tianda Tianfa Technol-
ogy Co., Ltd,Tianjin, China). Each vessel was filled with 500 ml
of 0.07% Tween 80 media, which was degassed before the dis-
solution tests proceeded and equilibrated at 37 °C.The rotation
speed was set at 50 rpm. 5 ml of samples were withdrawn at
5, 10, 20, 30, 45 and 60 min, the same amount of fresh medium
were replaced at predetermined time intervals. Then with-
drawn samples filtered through 0.45 μm filters. Dissolution for
each formulation was carried out in triplicate (n = 3). With-
drawn samples were measured by HPLC method.
2.5. In vivo pharmacokinetic study
2.5.1. Animals
The in vivo pharmacokinetic study was conducted with ethical
permission,which was permitted by Ethical Committee in China
and was processed in accordance with the Guide for the Care
and Use of Laboratory Animals.The pharmacokinetic study of
three lacidipine formulations was performed on six beagle dogs
weighing 12–16 kg.These dogs were divided into 3 groups ran-
domly, and the study was carried out in a crossover
experimental design with a washout period of one week. The
dogs were fasted for about 12 h prior to experiments and were
given water freely. The preparations were administered orally
at a single dose of 4 mg. 2.0 ml of blood samples were taken
into a heparinized blood collection tube via a detaining needle
at pre-dose, and 0.25, 0.50, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0,
12.0 and 24.0 h post-dose.The dogs were provided with a stan-
dard lunch 4 h after dosing. The plasma was obtained by
centrifuging the blood samples at 3500 rpm for 10 min, and
stored at −20 °C.
2.5.2. Bioanalytical method
The lacidipine plasma concentrations were determined by a
validated ultra performance liquid chromatography-dual mass
spectrometry (UPLC-MS/MS) method after liquid–liquid ex-
traction by tert-butyl methyl ether with nimodipine as internal
standard. The chromatographic separations were acquired on
an ACQUITY UPLC™ system (Waters Corp., Milford, MA, USA)
and Thermo C18 column (50 mm × 2.1 mm, 2.6 μm; Thermo
Fisher Scientific, USA) with a mobile phase composed of ace-
tonitrile and water containing 0.1% formic acid (83:17; v/v) at
a flow rate of 0.2 ml/min. The quantitation was performed by
Waters Tandem Quadrupole (TQ) Detector (Waters). The mass
spectrometer was operated with electrospray ionization (ESI)
source in positive ionization mode and the compounds were
analyzed by multiple reaction monitoring (MRM) of the tran-
sitions of m/z 473.47→354.28 for lacidipine and m/z
419.25→343.18 for nimodipine, respectively.
2.5.3. Data analysis
Non-compartmental model analysis was conducted to calcu-
late the main pharmacokinetic parameters. The maximum
plasma drug concentration (Cmax) and the time (Tmax) to reach
Cmax of the three formulations were directly gained from the
experimental data.The half-life (t1/2) was calculated using DAS
2.1.1 software. The area under the plasma concentration–
time curve up to the last measured time point (AUC0–t) was
determined using the trapezoidal rule. The relative
bioavailability (F) was the ratio between the test formula-










it was expressed as following equation:
AUC0–24 h, AUC0–∞ and Cmax make logarithmic transforma-
tion. ANOVA of lnAUC0–24 h, lnAUC0–∞ and lnCmax were calculated
for three formulations, and the threshold for differences to be
considered significant was set at P ≤ 0.05.Two one-sided t tests
were used to evaluate whether the 90% confidence intervals
(CIs) of the geometric mean ratios (test: reference) for Cmax,
AUC0–24 h and AUC0–∞ were within the range of 80.00%–125.00%
(using log transformed data).
2.6. Virtual bioequivalence study
2.6.1. PBPK model in dog based on the literature data
Physiologically based pharmacokinetic models are composed
of a series of differential equations and have been imple-
mented in a number of commercial software packages. In this
study, all the in vivo PK simulations were conducted in the PBPK
model commercial software GastroPlus (Version 8.6.0003; Simu-
lations Plus, Inc., Lancaster, CA, USA). Input parameters in the
PBPK model can be categorized into three classes: physico-
chemical properties (such as solubility, pKa, LogP and
permeability), formulation properties (such as drug particle size
and dissolution profiles), and pharmacokinetic parameters (such
as clearance, volume of distribution, and the dispositionmodel).
The main drug-specific input parameters of log P, blood to
plasma partitioning, mean particle radius and Particle density
are in silico predicted by ADME Predictor. The Diffusion coef-
ficient, volume of distribution at steady state (Vss) and
elimination half-time in dog are calculated by GastroPlus
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equations. The lacidipine solubility in media and unbound
percent in plasma (Fup) in dogs is based from literatures [17,18],
respectively. The clearance (CL) is an important drug-specific
parameter required for PBPK modeling. Lacidipine is mainly
eliminated by hepatic metabolism, and renal clearance can be
negligible.The rate of hepatic metabolism in dogs is based from
a publication [19]. All these parameters for the simulation are
summarized in Table 2.
In our previous study, a PKPB model was successfully built
and validated to simulate PK parameters for the lacidipine in
dogs [17]. In this study, population pharmacokinetics simula-
tion of the three lacidipine formulations was carried out on
the successfully built PBPK model.
2.6.2. PK simulation for three lacidipine formulations in dogs
The in vivo PK simulations were conducted in the PBPK model
commercial software GastroPlus (Version 8.6.0003, Simula-
tions Plus, Inc., Lancaster, CA, USA).After all parameters (Table 2)
were imported into the successfully built PKPB model of
lacidipine, the dissolution profiles of the three formulations
in 0.07% Tween 80 solution were loaded to measure the effect
of formulations and dissolution conditions on the PK pro-
files. The imported physiology properties (such as blood flow,
volume of tissues, etc.) were changed within 3 times range to
conduct the virtual population pharmacokinetic simulation.
The change of the imported physiology properties param-
eters stimulated different dogs and resulted in different values
of Cmax and AUC. The dissolution profiles of the three formu-
lations in 0.07% Tween 80 solution that loaded to the model
could get the difference PK profiles of R, T1 and T2. After im-
porting 24 groups of physiology properties parameters, the PBPK
model commercial software GastroPlus outputted 24 groups
of Cmax and AUC for each formulation.
3. Results and discussion
3.1. In vitro dissolution study
Biorelevant media have been successfully adapted to simu-
late human small intestinal fluids and have been proven
valuable in establishing IVIVC for poorly soluble drugs [20,21].
In our previous work, we have investigated that 0.07% Tween
80 solution is a simple alternative medium to the simulated
fasted state intestinal fluid instead of the biorelevant media
[22]. In this study, the 0.07% Tween 80 media was chosen as
the dissolution media.
The dissolution profiles of three different lacidipine for-
mulations in 0.07% Tween 80 media are shown in Fig. 1. The
dissolution profile of three lacidipine formulations at 50 rpm
showed the 100% dissolution less than 1 h trailed by plateau
phase up to 4 h.The dissolution of capsules containing Soluplus
ASD of lacidipine was nearly complete (>85%) in media after
1 h, although the dissolution rate was slightly slower than other
two formulations. It concluded that the self-made Soluplus ASD
and HPMC-E5 ASD of lacidipine exhibited similar dissolution
behavior compared with that of LACIPIL® in 0.07% Tween 80
media. According to their in vitro dissolution results, the three
different lacidipine formulations in 0.07%Tween 80 media may
have perfect bioequivalence in vivo performances.
3.2. In vivo pharmacokinetic study
3.2.1. Pharmacokinetic parameters study
The relevant pharmacokinetics parameters are listed in Table 3,
and the mean concentration–time profiles of three formula-
tions of lacidipine are shown in Fig. 2. The maximum plasma
drug concentration (Cmax) values of the reference and the two
test formulations were 24.45 ± 6.53, 28.80 ± 11.89 and
26.647 ± 4.44 respectively.This indicated that the three lacidipine
formulations have comparable values of Cmax. The mean Tmax
values of the reference and the two test formulations were
1.13 ± 0.70, 1.29 ± 0.64 and 1.79 ± 1.36 respectively. Regarding the
absorption rate, reference and HPMC-E5 ASD of lacidipine (T1)
had shorter time to reach the Cmax than Soluplus ASD of
lacidipine (T2). The Soluplus ASD of lacidipine (T2) had larger
Tmax values than the other two formulations, indicating that
the Soluplus ASD of lacidipine (T2) exhibited a slow in vivo





Dog permeability (Peff, cm/sec × 104) 2.5a
Mean particle radius (μm) 25b
Mean precipitation time (sec) 900b
Particle density (g/ml) 1.2b
Diffusion coefficient (cm2/sec × 105) 0.6139c
Solubility (mg/ml) 5 × 10−5 in blank FaSSIFd
Unbound percent in plasma (Fup, %) 5d
Clearance (CL, l/h) 9.6d
Volume of distribution (Vss, l) 159.45c
Elimination half-time (T1/2, h) 11.5c
Simulation time (h) 24
a Predicted by ADME Predictor.
b Default GastroPlus™.
c Calculated by GastroPlus™.
d Literature value17–19.
Fig. 1 – Dissolution profiles of three lacidipine formulations
in 0.07% Tween 80 media. Data are presented as the
mean ± SD (n = 3). (The reference formulation of lacidipine
(R), lacidipine/HPMC-E5 capsules (T1) and lacidipine/
Soluplus capsules (T2)).
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dissolution rate, and the result was similar to the in vitro dis-
solution rate of T2 in 0.07% Tween 80 media. The relative
bioavailability of HPMC-E5 ASD of lacidipine (T1) compared with
the reference was 112.2% ± 57.8%, and the Soluplus ASD of
lacidipine (T2) compared with the reference was 110.6% ± 51.6%.
Both of two test formulations slightly enhance the
bioavailability.
3.2.2. Bioequivalent analysis
If the 90% CIs of the geometric mean ratios (test: reference)
for Cmax, AUC0–24 h and AUC0–∞ was within the range of 80.00%–
125.00%, the test formulations and the reference were
considered bioequivalent [23]. The two one-sided t tests and
90% CIs results of AUC and Cmax were summarized in Tables 4
and 5.Wilcoxon signed test of Tmax was summarized in Table 6.
As shown in Table 4, the 90% CIs of the geometric mean
ratios (test: reference) for AUC0–24 h and AUC0–∞ was not within
the range of 80.00%–125.00% by using AUC as the evaluation
parameters. Additionally, Table 5 showed that 90% CIs of the
geometric mean ratios (test: reference) for Cmax was not within
the range of 80.00%–125.00% by using Cmax as the evaluation
parameters. Wilcoxon signed test results (Table 6) of Tmax
between the reference and the two test formulations indi-
cated no significant difference (P > 0.05) [3].
In in vitro dissolution experiments, the results indicated that
both the reference and the two test formulations could totally
dissolve within 1 h, so the three formulations had compa-
rable dissolution.The dissolution rate of Soluplus ASD in 0.07%
Tween 80 media was slightly slower than the other two for-
Table 3 – Pharmacokinetic parameters for lacidipine formulations including R, T1 and T2 (Data were shown as mean ± SD,
n = 6)
PK parameters R T1 T2
Cmax (ng/ml) 24.45 ± 6.53 28.80 ± 11.89 26.647 ± 4.44
Tmax (h) 1.13 ± 0.70 1.29 ± 0.64 1.79 ± 1.36
t1/2 (h) 8.39 ± 4.60 7.10 ± 6.73 5.20 ± 6.16
AUC0-24 (ng·h/ml) 89.16 ± 34.63 87.73 ± 35.72 89.29 ± 31.87
AUC0-∞ (ng·h/ml) 109.37 ± 58.12 94.48 ± 40.38 96.97 ± 40.73
F (%) 100 112.2 ± 57.8 110.6 ± 51.6
Fig. 2 – Plasma concentration–time profiles for lacidipine
commercial tablets and lacidipine ASDs after oral
administration of 4 mg in beagle dogs (data are shown as
mean ± SD, n = 6).
Table 4 – Two one side t-test results of main parameters between T1 and R.
Parameters t1 t2 t1–0.05(4) 90% Confidence
AUC0–24 0.777 0.999 t1 < t1–0.05(4), t2 < t1–0.05(4) 49.8%∼156.1%
AUC0–∞ 0.315 1.138 t1 < t1–0.05(4), t2 < t1–0.05(4) 56.8%∼132.8%
Cmax 2.203 1.088 t1 > t1–0.05(4), t2 < t1–0.05(4) 75.4%∼169.0%
Table 5 – Two one side t-test results of main parameters between T2 and R.
Parameters t1 t2 t1-0.05(4) 90% Confidence
AUC0–24 0.950 0.826 t1 < t1–0.05(4), t2 < t1–0.05(4) 63.6%∼162.1%
AUC0–∞ 0.459 0.993 t1 < t1–0.05(4), t2 < t1–0.05(4) 52.0%∼163.1%
Cmax 2.127 1.165 t1 > t1–0.05(4), t2 < t1–0.05(4) 74.2%∼166.3%
Table 6 – Wilcoxon signed test results of Tmax between R and T1.
R T1 T2 P Conclusion
Mean ± SD 1.13 ± 0.70 1.29 ± 0.64 1.79 ± 1.36 >0 .05 Meeting
the criteriaMax–Min 2.00–0.50 2.00–0.50 4.00–0.75
Median 0.88 1.25 1
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mulations, and the dissolution rate of Soluplus ASD in vivo
exhibited the same results. However, bioequivalent analysis in-
dicated that the reference and the two test formulations were
inequivalent in the beagle dog in vivo experiment.The sample
size and variability influenced the outcome of bioequivalent
study other than true differences in Cmax and/or AUC between
reference and test formulations. So it might be related with
the less experimental animal sample and inter-subject vari-
ability [24].
3.3. Virtual bioequivalent analysis
To investigate whether the formulations would be bioequivalent
with a large group of experimental animal subjects, the PBPK
modeling built in above section was used to simulate phar-
macokinetics for the three formulations [17]. A virtual
bioequivalent study was conducted to analyze that pharma-
cokinetics of formulations was influenced by the inter-subject
physiological variability.
Fig. 3 showed that the mean plasma concentration–time
curves of the reference tablet (R) and the test formulations (T1
and T2) all fall in the 90% CIs. The 90% CIs of the geometric
mean ratios (T2: R) for bioequivalent analysis obtained from
virtual crossover bioequivalent study was narrower than the
90% CIs of the geometric mean ratios (T1: R) for bioequivalent
analysis. Meanwhile, the simulated mean plasma
concentration–time curve of the reference tablet (R) was covered
by the 90% CIs of T1. As shown in Table 7, the 90% CIs of the
geometric mean ratios (test: reference) for Cmax and AUC was
within the requested range as well as meeting the conditions
of bioequivalence when the experimental animal sample
reached 24.The results here further demonstrated that the ref-
erence and the two test formulations were inequivalent when
6 beagle dogs involved in the experiment had inter-subject
physiological variability. However, three formulations were
equivalent when studying with a large sample.
The 90% CIs of the geometric mean ratios (test: reference)
for bioequivalent analysis obtained from virtual crossover
bioequivalent study were narrower than the results getting from
experimental data in vivo study. During the simulation experi-
ment, the same subject had identical physiological and
pharmacokinetics parameters when they were administered
with the reference and the two test formulations, whereas the
physiological and pharmacokinetics parameters of the same
subject would be influenced in different occasions, different
times or after giving various formulations in an actual experi-
ment [25].
In our previous study, the PBPK model has been validated
to simulate PK parameters for the lacidipine self-made mi-
cronized tablet and commercial tablets in dogs compared with
the observed. In this study, the PBPK model was used as an
auxiliary approach to determine bioequivalent study and help
reduce the number of animals used.With the ability to predict
the input parameters for improving PBPK models, PK can be
accurately predicted using in silico inputs only [5].
4. Conclusions
The in vitro dissolution profiles of three formulations between
the reference and the tests exhibited similar dissolution be-
havior in 0.07% Tween 80 media. With the less experimental
animal sample and inter-subject variability, bioequivalent analy-
sis indicated that the reference and the two test formulations
were inequivalent in the beagle dog in vivo experiment.Through
the population pharmacokinetics simulation using PBPKmodel
Fig. 3 – Virtual bioequivalent study of reference tablet (R) and test formulations (T1 and T2) in 24 beagles.
Table 7 – Summary of Virtual BE Studies for lacidipine
formulations.
Parameters T1 vs. R T2 vs. R
Mean
ratio
90% CI Mean 90% CI
Cmax 1.01 81.6% ~ 124% 1.10 98.4% ~ 123.2%
AUC0–24 1.00 85.8% ~ 115.7% 0.94 87.5% ~ 102.0%
AUC0–∞ 1.00 85.4% ~ 116.2% 0.95 87.8% ~ 101.7%
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and virtual bioequivalent analysis with 24 virtual subjects, the
90% CIs of the geometric mean ratios (test: reference) for Cmax
andAUCwere within the requested BE range as well as meeting
the conditions of bioequivalence. Thus, the virtual BE studies
will play a potentially useful tool for drug development field.
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